PTAP

SE Healthcare Announces Groundbreaking Alignment with Magnet®, Pathway to Excellence®, and PTAP Standards through its Nurse Burnout Prevention Program

Retrieved on: 
Wednesday, April 24, 2024
Magnet, Hospital, Health care, Innovation, Nursing, Accreditation, Health, Patient satisfaction, PTAP

PITTSBURGH, April 24, 2024 /PRNewswire-PRWeb/ -- SE Healthcare, the leader in combating nurse burnout, providing evidence-based, comprehensive solutions that improve nurse retention, proudly announces the success of its Nurse Burnout Prevention Program in aligning with the prestigious standards of the Magnet Recognition Program®, Pathway to Excellence®, and Practice Transition Accreditation Program® (PTAP).

Key Points: 
  • PITTSBURGH, April 24, 2024 /PRNewswire-PRWeb/ -- SE Healthcare, the leader in combating nurse burnout, providing evidence-based, comprehensive solutions that improve nurse retention, proudly announces the success of its Nurse Burnout Prevention Program in aligning with the prestigious standards of the Magnet Recognition Program®, Pathway to Excellence®, and Practice Transition Accreditation Program® (PTAP).
  • Our Nurse Burnout Prevention Program is meticulously designed to support the core values of Magnet®, Pathway to Excellence®, and PTAP standards.
  • The Nurse Burnout Prevention Program, leveraged by top hospitals and healthcare systems, integrates cutting-edge technology with evidence-based practices to significantly mitigate burnout.
  • Dr. Andrea Coyle, Chief Clinical and Innovation Officer at SE Healthcare, states, "Our Nurse Burnout Prevention Program is meticulously designed to support the core values of Magnet®, Pathway to Excellence®, and PTAP standards.

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, HCPCS, Gait, Patient, Operating cost, Stroke, Sale, Acquisition, HSDT, Andreyev, Social services, ATM, Pons, Medicare, FDA, CMS, PTAP, Food, Video game

NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2023.

Key Points: 
  • Gross profit for the fourth quarter of 2023 was $44 thousand, compared to gross profit of $132 thousand in the fourth quarter of 2022.
  • Operating loss for the fourth quarter of 2023 decreased to a loss of $2.2 million, compared to an operating loss of $2.7 million in the fourth quarter of 2022.
  • Net loss was $1.0 million for the fourth quarter of 2023, compared to a net loss of $4.9 million in the fourth quarter of 2022.
  • The basic and diluted net loss per share for the fourth quarter 2023 was $1.47, compared to net loss per share of $8.66 in the fourth quarter 2022.

Helius Medical Technologies, Inc. Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
School, Social services, Pons, Gait, TBI, Patient, HCPCS, UPC, Andreyev, PTAP, Research, HSDT, Wolters Kluwer, Accreditation, Stroke, Rehabilitation, Multiple sclerosis, Letter, Pacific Blue Cross, Pharmaceutical industry, Cryptocurrency, Security (finance), Health insurance, Video game, Helios, Health

NEWTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended September 30, 2023.

Key Points: 
  • NEWTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended September 30, 2023.
  • Together with the previously announced Durable Medical Equipment, Prosthetics, Orthotics and Supplies (“DMEPOS”) accreditation, the UPC numbers allow for dual paths of reimbursement.
  • Research and development expenses for the third quarter of 2023 decreased slightly to $722 thousand, compared to $751 thousand in the third quarter of 2022.
  • Total operating expenses for the third quarter of 2023 decreased to $3.1 million, compared to $4.9 million in the third quarter of 2022.

Helius Medical Technologies, Inc. to Release Third Quarter 2023 Financial Results on November 9, 2023; Announces Extended Cash Runway into Q2 2024

Retrieved on: 
Thursday, November 2, 2023
PTAP, HSDT, Patient, Pharmaceutical industry

NEWTOWN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its third quarter 2023 financial results on Thursday, November 9, 2023, after the market closes.

Key Points: 
  • -- Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023 --
    -- Expects to report approximately $7.0 million in cash, cash equivalents and proceeds receivable from warrant exercises, extending cash runway into Q2 2024 --
    -- Expects to report cash used in operating activities for the first nine months of 2023 ranging from $8.3 - $8.4 million, and for Q3 $2.4 - $2.5 million, reflecting continued focus on cash management --
    NEWTOWN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its third quarter 2023 financial results on Thursday, November 9, 2023, after the market closes.
  • Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius’ progress and plans surrounding the U.S. commercialization of PoNS® as follows:

Helius Medical Technologies, Inc. Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Survivor, Montefiore Medical Center, CMS, Accreditation, Stroke, Gait, Centers for Medicare & Medicaid Services, Pons, HSDT, The Compliance Team, Medical school, Multiple sclerosis, MS, TCT, Food and Drug Administration, Medicare, Andreyev, ATM, Medical University of South Carolina, Patient, PTAP, MUSC, Growth, Research, FDA, Durable medical equipment, Pharmaceutical industry, Health insurance, Video game, Cryptocurrency, Helios

NEWTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended June 30, 2023.

Key Points: 
  • “We saw a significant increase in sales during the second quarter of 2023, with revenue up 115% over the second quarter of 2022, and up 131% compared to the first quarter of 2023.
  • Selling, general and administrative expenses for the second quarter of 2023 were $2.6 million, comparable to the $2.5 million reported in the second quarter of 2022.
  • Total operating expenses for the second quarter of 2023 decreased to $3.3 million, compared to $3.5 million in the second quarter of 2022.
  • Operating loss for the second quarter of 2023 decreased $0.2 million to a loss of $3.2 million, compared to an operating loss of $3.4 million in the second quarter of 2022.

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 9, 2023
MS, Pons, Clinical trial, HSDT, Introduction, Management of multiple sclerosis, Andreyev, PTAP, Patient, Therapy, Stroke, Health, Center of excellence, Operating cost, Prescription, Video game, Pharmaceutical industry, Cryptocurrency, Helios

NEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2022.

Key Points: 
  • Gross profit for the fourth quarter of 2022 was $132 thousand, compared to gross profit of $129 thousand in the fourth quarter of 2021.
  • Operating expenses for the fourth quarter of 2022 decreased to $2.8 million, compared to $4.2 million in the fourth quarter of 2021.
  • Operating loss for the fourth quarter of 2022 decreased $1.4 million to a loss of $2.7 million, compared to an operating loss of $4.1 million in the fourth quarter of 2021.
  • The basic and diluted net loss per share for the fourth quarter 2022 was $0.17, compared to net loss per share of $1.31 in the fourth quarter 2021.

Helius Medical Technologies, Inc. Announces Participation of Neurology Center of New England in its Therapeutic Experience Program

Retrieved on: 
Tuesday, January 10, 2023
Multiple sclerosis, Disease, HSDT, MS, PTAP, Naples, Pons, Gait, Excellent, Patient, Management of multiple sclerosis, P.C, Health, TEP, Pharmaceutical industry

NEWTOWN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the addition of Neurology Center of New England, P.C. (“NCNE”) to its Therapeutic Experience Program (TEP). NCNE joins four other Centers of Excellence in this company-sponsored open-label observational trial designed to evaluate the impact of subjects’ adherence to Portable Neuromodulation Stimulator (PoNS) therapy in patients with multiple sclerosis (MS). The initiative will be led by Dr. Salvatore Napoli, Medical Director of NCNE.

Key Points: 
  • (“NCNE”) to its Therapeutic Experience Program (TEP).
  • The initiative will be led by Dr. Salvatore Napoli, Medical Director of NCNE.
  • Napoli and his team are important contributors to our PTAP program, and we are elated about their participation in the TEP study.
  • NCNE is a highly reputable medical center known for its high-touch, integrated approach to treating MS and other neurological conditions.

Helius Extends its Patient Therapy Access Program (PTAP), Bringing the Benefits of its PoNS® Device to More People with Multiple Sclerosis

Retrieved on: 
Thursday, January 5, 2023
Multiple sclerosis, Gait, HSDT, Patient, Pons, MS, Brain, Caregiver, Nerve, Helios, Rehabilitation, Letter, Walking, Exercise, PTAP, Tongue

This initiative, the Patient Therapy Access Program (PTAP), launched in June 2022 and was slated to expire at the end of last year.

Key Points: 
  • This initiative, the Patient Therapy Access Program (PTAP), launched in June 2022 and was slated to expire at the end of last year.
  • PTAP is now active until June 30, 2023, reflecting high interest in a program that partially subsidizes PoNS Therapy™ for people with MS who qualify through a proper prescription and letter of medical necessity.
  • When paired with an exercise regimen supervised by a rehabilitation specialist, this activity improves gait impairment in people with MS .
  • When someone’s gait is impaired the stakes are often too high not to explore every opportunity for improvement.”

Helius Medical Technologies, Inc. Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 14, 2022
Holiday, OHSU, Patient, Oregon Health & Science University, Oregon Health and Science University Center for Women's Health, Excellent, Pons, HSDT, NYU Langone Health, PTS, Massachusetts General Hospital, TEP, Research, MGH Institute of Health Professions, Growth, PTAP, Therapy, Pharmaceutical industry, Video game, Helios

NEWTOWN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • NEWTOWN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended September 30, 2022.
  • It was the first full quarter of commercial sales and the market response to PoNS Therapy remains strong, as demonstrated by the quarter over quarter increase in US sales.
  • Product sales in the U.S. during the third quarter totaling $139 thousand more than doubled over the second quarter 2022 levels.
  • Operating expenses for the third quarter of 2022 increased to $4.9 million, compared to $4.4 million in the third quarter of 2021.

HSS Nurse Residency and Peri-Operative Fellowship Programs Achieve Accreditation from ANCC

Retrieved on: 
Thursday, October 27, 2022
Magnet, DNP, APRN, ANA, ANCC, Weill Cornell Medicine, Hospital for Special Surgery, Accreditation, The Hospital, Organization, Research, American Nurses Credentialing Center, Program, RN, Environment, Physician, Health, Spine, News, MD, Education, American Nurses Association, Multimedia, HSS, Preceptor, Therapy, PTAP, Acquisition, MBA, Long Island, COVID-19, Workforce, Rheumatology, U.S. News & World Report, Hospital, Fellow, Infection, Foot, Knowledge, Elective surgery, Laboratory, Leadership, MS, Medicine, Newsweek, Hand, Nursing, Sport

NEW YORK, Oct. 27, 2022 /PRNewswire/ -- The Nurse Residency Program and Peri-Operative Fellowship Program at Hospital for Special Surgery (HSS), the world's leading academic medical center focused on musculoskeletal health, have achieved Practice Transition Accreditation from the American Nurses Credentialing Center (ANCC).

Key Points: 
  • "The ANCC accreditation, an industry-leading certification for nursing excellence, signals HSS's longstanding commitment to the nursing profession and individual career development," said Paul Coyne, DNP, MBA, MS, APRN, AGPCNP-BC, senior vice president and Chief Nurse Executive at HSS.
  • "The program provides a strong foundation for the novice nurse and we're especially grateful to our outstanding nursing preceptors for their residency program leadership and mentorship.
  • "This accreditation is a welcome validation of the unprecedented opportunity for nurses to realize their potential at HSS."
  • In addition, ANCC provides leading-edge information and education services and products to support its core credentialing programs.